Investors
Building the governance layer for AI-assisted clinical work.
VGSI is a Portuguese healthcare AI product company. We begin with a bounded and measurable problem: supporting clinical coding through source-linked evidence, mandatory human review and a traceable decision record.
SICC is a working MVP preparing for institutional evaluation. Morpheus remains investigational.
Company today
Company-reported facts.
- Founded
- 27 June 2026
- Headquarters
- Braga, Portugal
- Stage
- Early-stage · Pre-revenue
- Founder funding
- €180k
- External capital raised
- €0
- SICC
- Working MVP
- Morpheus
- Research and development
- Next milestone
- Institutional-evaluation readiness
Company-reported information as of 15 August 2026. Founder funding is not an external financing round.
The thesis
A focused entry point into a structural problem.
Clinical coding turns complex documentation into data used for morbidity reporting, planning, audit, financing and healthcare operations.
VGSI's thesis is straightforward: an AI suggestion only becomes usable in this workflow when a professional can verify its supporting evidence, retain the final decision and reconstruct the decision path.
That is the difference between generating an answer and building governed AI.
Market opportunity
Demonstrable scale. A serviceable market still to be proven.
In 2023, the European Union recorded 68.2 million inpatient discharges and 46.9 million day-case discharges: more than 115 million episodes. [1]
In mainland Portugal, the Health Regulatory Authority reported 62.1 hospital admissions per 1,000 inhabitants in 2024, based on the NHS Transparency Portal. [2]
These figures demonstrate workflow scale. They are not financial TAM estimates and do not assume that every episode is addressable by SICC.
Initial market
Portuguese hospitals with coding, audit, quality and clinical-operations teams.
Potential expansion
European institutions with comparable workflows, subject to national adaptation, integration and regulation.
Long-term ambition
Apply the evidence, review and traceability architecture to adjacent clinical workflows after SICC's value has been demonstrated.
The monetisable market will be calculated bottom-up: eligible institutions × validated annual contract value. VGSI will not publish a speculative euro TAM before procurement, integration, pricing and institutional use have been validated.
The measurable problem
Volume, detail and accountability in tension.
Portuguese ICD-10-CM/PCS coding may require review of discharge notes, progress notes, emergency records, operative reports, pathology and other authorised sources.
In a national study of 103 Portuguese medical coders, 59.2% reported needing more time per episode after the transition to ICD-10-CM/PCS, while 73.8% considered the resulting coded data to be of higher quality. [3]
SICC is designed around this tension between volume, detail and accountability. Rather than publish an unvalidated time-saving or accuracy figure, VGSI intends to establish each institution's baseline and measure jointly agreed outcomes.
Sources and methodology
Public data supporting these figures.
- [1] Eurostat — Hospital discharges and length of stay statistics, 2023 data
- [2] Portuguese Health Regulatory Authority — Study on Local Health Units, 2024 indicators
- [3] Health Information Management Journal / PubMed — Portuguese medical coders' perceptions of the ICD-10-CM/PCS transition
The sources describe external context; they are not VGSI traction or validated SICC performance.
The wedge
Governed AI from the first workflow.
SICC organises documentation, presents candidate codes and connects each suggestion to its supporting passages. The authorised professional accepts, modifies or rejects the proposal and retains the final decision.
Differentiation is built around:
Mandatory human review
Traceable states and changes
Institution-defined evaluation criteria
Preparation for integration, security and audit
Where we are
What is built — and what we do not claim.
Built
- Incorporated and founder-funded company
- Working SICC MVP
- Documentation, suggestion, evidence and review workflow
- Morpheus in research and development
Not yet claimed
- Production hospital deployment
- Recurring revenue
- Clinical outcomes
- Validated reductions in time or error
- Completed institutional validation
Roadmap
An evidence-gated roadmap.
Morpheus follows a separate investigational pathway gated by technical and clinical evidence, data rights and regulatory assessment.
Evaluation readiness
Define the workflow, scope, data, responsibilities, baseline, success criteria and institutional requirements.
Controlled institutional evaluation
Assess SICC within an agreed scope, under professional oversight and against criteria established in advance.
Production readiness
Strengthen security, observability, interoperability, performance and compliance documentation based on results.
Commercial repeatability
Progress to a recurring model only when evidence, integration, procurement and product economics support it.
Commercial model
A B2B hypothesis yet to be validated.
The current hypothesis is institution-facing B2B software: begin with a bounded evaluation and progress to a recurring agreement when results, security, integration and procurement requirements are satisfactory.
This hypothesis has not yet been validated by revenue and may evolve through institutional learning.
Capital
Capital for the next evidence gates.
VGSI welcomes selected conversations with investors focused on European healthtech, enterprise software, governed AI and clinical infrastructure.
Potential external capital would support:
- Product engineering, security and interoperability
- Preparation and execution of institutional evaluations
- Evidence generation and governance processes
- Selective hiring and institutional commercial development
VGSI does not currently publish a valuation, instrument or formal round terms. Those will be communicated once defined and approved.
Investor deck
Request VGSI's current investor deck.
We share the deck on request with investors whose thesis includes healthcare AI, clinical software or European enterprise technology. Additional diligence material will be provided selectively as it becomes available and, where appropriate, under confidentiality.